Table 1 Patient characteristics, distribution, and total RNA preparation method

#1

Pre-pre-B-ALL

95

t(4;11)

6 m

A,B,C

3

#2

c-ALL

70

t(9;22)

14 y

A,B,C

3

#3

Early-T-ALL

83

negative

16 y

A,B,C

3

#4

c-ALL

90

t(12;21)

13 y

A,B,C

3

#5

Pre-B-ALL

98

t(1;19)

10 y

A,B,C

3

#6

c-ALL

87

hyperdiploid (DI = 1,233)

2 y

A,B,C

3

#7

c-ALL

93

negative

16 y

A,B,C

3

#8

AML

89

negative*

16 y

A,B,C

3

#9

c-ALL/Pro-B

85

t(9;22)

5 y

A,B,C

3

#10

Early-T-ALL

94

negative

4 y

A,B,C

3

#11

c-ALL

88

t(12;21)

2 y

A,B,C

3

#12

prepreB/c-ALL

96

Hyperdiploid (DI = 1,244)

11 y

A,B,C

3

#13

c-ALL

95

negative

3 y

A,B,C

3

#14

Pre-B-ALL

87

negative

12 y

A,B,C

3

#15

c-ALL

94

t(12;21)

8 y

A,B,C

3

#16

AML

93

t(9;11)

6 y

A,B,C

3

#17

Early-T-ALL

87

negative

9 y

A,B,C

3

#18

Early-T-ALL

93

negative

9 y

A,B,C

3

#19

c-ALL

93

hyperdiploid (DI = 1,160)

2 y

A,B,C

3

#20

prepreB/c-ALL

85

negative

3 y

A,B,C

3

#21

mature T-ALL

94

negative

4 y

A,B,C

3

#22

Pre-B-ALL

95

negative

7 y

A,B,C

3

#23

prepreB/c-ALL

94

negative

4 y

A,B,C

3

#24

c-ALL

86

negative

5 y

A,B,C

3

TOTAL

72

#25

AML

89

negative**

4 y

A,A,A,B,B,B,C,C,C

9

#26

AML

77

t(1;11)

6 m

A,A,A,B,B,B,C,C,C

9

#27

prepreB/CALL

92

negative

4 y

A,A,A,B,B,B,C,C,C

9

TOTAL (replicates)

27

TOTAL in Study

99